Correction: Preclinical evaluation of biomarkers associated with antitumor activity of MELK inhibitor

PDF  |  How to cite

Oncotarget. 2020; 11:3749-3750. https://doi.org/10.18632/oncotarget.27755

Metrics: PDF 73 views  |   ?  

Suyoun Chung1, Kyoko Kijima1, Aiko Kudo1, Yoshiko Fujisawa1, Yosuke Harada1, Akiko Taira1, Naofumi Takamatsu1, Takashi Miyamoto1, Yo Matsuo1 and Yusuke Nakamura2

1 OncoTherapy Science, Inc., Kawasaki, Kanagawa, Japan
2 Department of Medicine and Surgery, The University of Chicago, Chicago, IL, USA

Published: October 13, 2020

Copyright: © 2020 Chung et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

This article has been corrected: During image assembly, incorrect data was mistakenly used in Figure 5A, resulting in a duplicate image of the bottom two panels. The corrected Figure 5A is shown below. The authors declare that these corrections do not change the results or conclusions of this paper.

Original article: Oncotarget. 2016; 7:18171–18182. DOI: https://doi.org/10.18632/oncotarget.7685.

Figure 5: Molecular changes in OTS167-treated tumor tissue. Immunohistochemical analysis using xenograft tissue collected on day 4. (A) DEPDC1, (B) FOXM1, (C) p21, and (D) p53 were examined (original magnification: x 400). Box plots represent the percentage of positive cells stained with each antibody. Horizontal lines represent mean and error bars indicating the interquartile ranges of 30 ROIs per group. *p < 0.0001 by ANOVA and t t-test.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27755